Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

NCT06704620 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

430

Enrollment

OTHER

Sponsor class

Conditions

Advanced and Metastatic NSCLC

Interventions

DRUG: Diphenhydramine
DRUG: Tislelizumab
DRUG: Pemetrexed
DRUG: Albumin paclitaxel
DRUG: Carboplatin
DRUG: Cisplatin

Sponsor

Tianjin Medical University Cancer Institute and Hospital